Advanced

Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT)

Socie, Gerard; Mary, Jean-Yves; Schrezenmeier, Hubert; Marsh, Judith; Bacigalupo, Andrea; Locasciulli, Anna; Fuehrer, Monica; Békássy, Albert LU ; Tichelli, Andre and Passweg, Jakob (2007) In Blood 109(7). p.2794-2796
Abstract
Previous studies suggested a link between the use of G-CSF and increased incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after immunosuppressive therapy (IST) for severe aplastic anemia (SAA). This European survey included 840 patients who received a first-line IST with (43%) or without (57%) G-CSF. The incidences of MDS/AML in patients who did or did not receive G-CSF were 10.9% and 5.8%, respectively. A significantly higher hazard (1.9) of MDS/AML was associated with use of G-CSF. Relapse of aplastic anemia was not associated with a worse outcome in patients who did not receive G-CSIF as first therapy, whereas relapse was associated with a significantly worse outcome in those patients who received G-CSF.... (More)
Previous studies suggested a link between the use of G-CSF and increased incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after immunosuppressive therapy (IST) for severe aplastic anemia (SAA). This European survey included 840 patients who received a first-line IST with (43%) or without (57%) G-CSF. The incidences of MDS/AML in patients who did or did not receive G-CSF were 10.9% and 5.8%, respectively. A significantly higher hazard (1.9) of MDS/AML was associated with use of G-CSF. Relapse of aplastic anemia was not associated with a worse outcome in patients who did not receive G-CSIF as first therapy, whereas relapse was associated with a significantly worse outcome in those patients who received G-CSF. These results emphasize the necessity of the current European randomized trial comparing IST with or without G-CSF and to alert physicians that adding G-CSIF to IST is currently not standard treatment for SAA. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood
volume
109
issue
7
pages
2794 - 2796
publisher
American Society of Hematology
external identifiers
  • wos:000245639000028
  • scopus:33947594348
ISSN
1528-0020
DOI
10.1182/blood-2006-07-034272
language
English
LU publication?
yes
id
a0825b9c-a656-41e6-aa6c-4e70f46b2885 (old id 666560)
date added to LUP
2007-12-14 16:41:23
date last changed
2017-11-19 03:40:13
@article{a0825b9c-a656-41e6-aa6c-4e70f46b2885,
  abstract     = {Previous studies suggested a link between the use of G-CSF and increased incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after immunosuppressive therapy (IST) for severe aplastic anemia (SAA). This European survey included 840 patients who received a first-line IST with (43%) or without (57%) G-CSF. The incidences of MDS/AML in patients who did or did not receive G-CSF were 10.9% and 5.8%, respectively. A significantly higher hazard (1.9) of MDS/AML was associated with use of G-CSF. Relapse of aplastic anemia was not associated with a worse outcome in patients who did not receive G-CSIF as first therapy, whereas relapse was associated with a significantly worse outcome in those patients who received G-CSF. These results emphasize the necessity of the current European randomized trial comparing IST with or without G-CSF and to alert physicians that adding G-CSIF to IST is currently not standard treatment for SAA.},
  author       = {Socie, Gerard and Mary, Jean-Yves and Schrezenmeier, Hubert and Marsh, Judith and Bacigalupo, Andrea and Locasciulli, Anna and Fuehrer, Monica and Békássy, Albert and Tichelli, Andre and Passweg, Jakob},
  issn         = {1528-0020},
  language     = {eng},
  number       = {7},
  pages        = {2794--2796},
  publisher    = {American Society of Hematology},
  series       = {Blood},
  title        = {Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT)},
  url          = {http://dx.doi.org/10.1182/blood-2006-07-034272},
  volume       = {109},
  year         = {2007},
}